T2 Biosystems announces participate in NIJ-funded ARLG pilot study

T2 Biosystems announced participation in the NIH-funded Antibacterial Resistance Leadership Group, ARLG, pilot study for pneumonia patients. The Pneumonia Direct Pilot study is a prospective, observational, diagnostic, feasibility study to determine the accuracy of multiple pathogen- and host-directed tests for the diagnosis of ventilator-associated pneumonia. Under the direction of Kimberly Hanson, M.D., University of Utah, the study seeks to explore new approaches for diagnosing VAP along with more comprehensive detection of antibiotic-resistant infections. The feasibility design is intended to inform future interventional studies that will investigate the clinical impact of combined pathogen and host-directed testing approaches. In the pilot study, the FDA-cleared T2Bacteria Panel and the T2Resistance(R) Panel, included as one of the pathogen directed platforms, will be evaluated for the ability to rapidly detect infections in the blood currently missed by conventional methods. The T2 sample testing for the multi-center study will be performed at Johns Hopkins Medicine laboratories. The extremely low level of detection by T2 Biosystems’ technology in whole blood has been effective in detecting secondary infections.